Travere Therapeutics, Inc. (TVTX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-14

Key Insights

The FDA has approved Travere Therapeutics' FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, marking the first FDA-approved therapy for this condition.
In the Phase 3 DUPLEX study, FILSPARI demonstrated statistically significant improvements in proteinuria reduction and eGFR preservation compared to the control treatment in patients with FSGS without nephrotic syndrome.
The addressable patient population for FILSPARI in FSGS without nephrotic syndrome is estimated to be over 30,000 individuals in the U.S., representing a significant commercial opportunity for the company.

Want the newest filings?

This analysis covers the filing from 2026-04-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-13

The FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), with a new Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026.
If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder that can lead to progressive kidney function loss and kidney failure.
The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI, and no additional information relating to the safety or manufacturing of FILSPARI has been requested.

Other reports for Travere Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.